 AlloVir Inc. said Thursday that its upsized initial public offering priced at 17 a share, in the middle of the expected range of 16 to 18 a share. The company sold 16.25 million shares to raise 276.25 million, up from previous expectations to sell 14.75 million shares. With 61.17 million shares outstanding after the IPO, the IPO pricing values the cell therapy company at about 1.04 billion. The lead underwriters of the IPO are Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler. The stock is expected to begin trading on the Nasdaq exchange under the ticker symbol ALVR. The company recorded a net loss of 9.3 million on no revenue over the three months through March 31, compared with a loss of 2.5 million on revenue of 165,000 a year ago. The company is going public at a time that the Renaissance IPO ETF has rallied 40.1 over the past three months, while the SP 500 has gained 11.9. 